TY - JOUR
T1 - Eradication of CD48-positive tumors by selectively enhanced YTS cells harnessing the lncRNA NeST
AU - Kotzur, Rebecca
AU - Stein, Natan
AU - Kahlon, Shira
AU - Berhani, Orit
AU - Isaacson, Batya
AU - Mandelboim, Ofer
N1 - Publisher Copyright:
© 2023 The Authors
PY - 2023/8/18
Y1 - 2023/8/18
N2 - Natural killer (NK) cells are currently used in clinical trials to treat tumors. However, such therapies still suffer from problems such as donor variability, reproducibility, and more, which prevent a wider use of NK cells therapeutics. Here we show a potential immunotherapy combining NK cell-mediated tumor eradiation and long non-coding (lnc) RNAs. We overexpressed the interferon (IFN) γ secretion-enhancing lncRNA nettoie Salmonella pas Theiler's (NeST) in the NK cell-like cell line YTS. YTS cells express the co-stimulatory receptor 2B4 whose main ligand is CD48. On YTS cells, 2B4 functions by direct activation. We showed that NeST overexpression in YTS cells resulted in increased IFNγ release upon interaction with CD48 (selectively enhanced (se)YTS cells). Following irradiation, the seYTS cells lost proliferation capacity but were still able to maintain their killing and IFNγ secretion capacities. Finally, we demonstrated that irradiated seYTS inhibit tumor growth in vivo. Thus, we propose seYTS cells as off-the-shelve therapy for CD48-expressing tumors.
AB - Natural killer (NK) cells are currently used in clinical trials to treat tumors. However, such therapies still suffer from problems such as donor variability, reproducibility, and more, which prevent a wider use of NK cells therapeutics. Here we show a potential immunotherapy combining NK cell-mediated tumor eradiation and long non-coding (lnc) RNAs. We overexpressed the interferon (IFN) γ secretion-enhancing lncRNA nettoie Salmonella pas Theiler's (NeST) in the NK cell-like cell line YTS. YTS cells express the co-stimulatory receptor 2B4 whose main ligand is CD48. On YTS cells, 2B4 functions by direct activation. We showed that NeST overexpression in YTS cells resulted in increased IFNγ release upon interaction with CD48 (selectively enhanced (se)YTS cells). Following irradiation, the seYTS cells lost proliferation capacity but were still able to maintain their killing and IFNγ secretion capacities. Finally, we demonstrated that irradiated seYTS inhibit tumor growth in vivo. Thus, we propose seYTS cells as off-the-shelve therapy for CD48-expressing tumors.
KW - Cancer
KW - Cellular therapy
KW - Components of the immune system
UR - http://www.scopus.com/inward/record.url?scp=85165361487&partnerID=8YFLogxK
U2 - 10.1016/j.isci.2023.107284
DO - 10.1016/j.isci.2023.107284
M3 - ???researchoutput.researchoutputtypes.contributiontojournal.article???
C2 - 37609636
AN - SCOPUS:85165361487
SN - 2589-0042
VL - 26
JO - iScience
JF - iScience
IS - 8
M1 - 107284
ER -